Open Access

Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer

  • Authors:
    • Shiho Kawagoe
    • Masahiro Nakano
    • Keita Uchino
    • Kohei Arimizu
    • Tatsuhiro Kajitani
    • Hozumi Shimokawa
    • Tetsuya Kusumoto
    • Koji Ikejiri
    • Eishi Baba
  • View Affiliations

  • Published online on: July 4, 2019     https://doi.org/10.3892/mco.2019.1894
  • Pages: 243-251
  • Copyright : © Kawagoe et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Response Evaluation Criteria in Solid Tumors (RECIST) is used to assess the objective response of solid tumors to treatment. However, it remains unclear to what extent the response rate assessed by RECIST reflects a reduction of tumor size in multiple organs in patients with unresectable advanced or recurrent colorectal cancer (CRC) with multiple organ metastases. It is also unclear whether the management of liver metastases with systemic chemotherapy in CRC patients with multiple organ metastases improves their prognosis, although surgical resection has been shown to be the most effective treatment approach to CRC cases with liver metastases. A total of 38 CRC patients who underwent systemic chemotherapy in Kyushu Medical Center Hospital between January 2013 and April 2016 were examined. The patients had measurable lesions in multiple organs, including the liver, and did not undergo curative surgery for metastatic lesions after initiation of chemotherapy. The association between the total reduction ratio (TRR) of all lesions and liver lesion reduction ratio (LRR) was retrospectively analyzed. A total of 18 patients (47%) had H3 liver metastases, and the median liver lesion occupancy rate in the sum of the measured lesions with RECIST was 76%. TRR and LRR were strongly correlated, regardless of the volume of the liver metastases. Although a TRR of >30% was significantly associated with improved overall survival (OS), this improvement was not observed in patients with H3 liver metastases. TRR was correlated with LRR and was associated with a better OS. CRC patients with both multiple organ and H3 liver metastases exhibited poor survival, even with a high reduction ratio by chemotherapy.

References

1 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of Worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J and Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surge. 244:254–259. 2006. View Article : Google Scholar

4 

Heinemann V, Stintzing S, Modest DP, Giessen-Jung C, Michl M and Mansmann UR: Early tumor shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer. 51:1927–1936. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al: ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 23:2479–2516. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, et al: Molecular markers and biological targeted in metastasis colorectal cancer: Expert opinion and recommendations derived from the 11th ESNO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol. 21 (Suppl 6):vi1–10. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY and Xu J: Randomized controlled trial of cetuximab plus chemotherapy for patients with LRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 31:1931–1938. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, et al: Tumor response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomized phase II trial. Lancet Oncol. 11:38–47. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al: Fluororacil, leucovorin, and oxaliplatin with and without cetuximab in the first line treatment of metastatic colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI

12 

Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluoriuracil, and leucovolin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Fakih MG: Metastatic colorectal cancer: Current state and future directions. J Clin Oncol. 33:1809–1824. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomized, open-label, phase III trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Osumi H, Matsusaka S, Suenaga M, Wakatsuki T, Ogura M, Ozaka M, Shinozaki E, Chin K and Mizunuma N: Quantitative analysis of the impact of deepness of response on survival time following patients with metastatic colorectal cancer treated by chemotherapy and anti-EGFR monoclonal antibodies. J Clin Oncol 32 (3 Suppl). S4932014. View Article : Google Scholar

17 

Peeters M, Price TJ, Cervantes A, Sobrero A, Ducreux MP, André T, Lordick F, Punt CJA, Koukakis R, Terwey J and van Custem E: Tumour shrinkage and response outcomes during second-line panitumumab (pmab) + FOLFIRI vs FOLFIRI treatment. Ann Oncol. 25 (Suppl 4):iv186–iv187. 2014. View Article : Google Scholar

18 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI

19 

Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A and Ychou M; European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop, : Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: Recommendations from an expert panel. Ann Oncol. 20:985–992. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Adam R, Lucidi V and Bismuth H: Hepatic colorectal metastases: Methods of improving resectability. Surge Clin North Am. 84:659–671. 2004. View Article : Google Scholar

21 

Pawlik TM and Choti MA: Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 11:1057–1077. 2007. View Article : Google Scholar : PubMed/NCBI

22 

Sharma S, Camci C and Jobbour N: Management of hepatic metastasis from colorectal cancers: An update. J Hepatobiliary Pancreat Surg. 15:570–580. 2008. View Article : Google Scholar : PubMed/NCBI

23 

Himuro N, Minakata T, Oshima Y, Kataoka D, Yamamoto S and Kadokura M: Prognostic indicators after resection of pulmonary metastases from colon and rectal cancer. J Jpn Assoc Chest Surg. 30:136–142. 2016. View Article : Google Scholar

24 

Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, Pignon JP and Ducreux M: Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol. 11:274–280. 2004. View Article : Google Scholar : PubMed/NCBI

25 

Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, et al: Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus. Cancer Treat Rev. 41:729–741. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Yoshidome H, kimura F, Shimizu H, Ohysuka M and Miyazaki M: Advances in surgical treatment for colorectal liver metastases. Nippon Shokakibyo Gakkai Zasshi. 106:1438–1446. 2009.(In Japanese). PubMed/NCBI

27 

Yang YY, Fleshman JW and Strasberg SM: Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases. J Gastrointest Surg. 11:929–944. 2007. View Article : Google Scholar : PubMed/NCBI

28 

Adam R: Developing strategies for liver metastases from colorectal cancer. Semin Oncol Apr 34 (2 Suppl 1). S7–S11. 2007.

29 

Lam VW, Spiro C, Laurence JM, Johnston E, Hollands MJ, Pleass HC and Richardson AJ: A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol. 19:1292–1301. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et al: Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Borner MM: Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer-too good to be true? Ann Oncol. 10:623–626. 1999. View Article : Google Scholar : PubMed/NCBI

32 

Cummings LC, Payes JD and Cooper GS: Survival after hepatic resection in metastatic colorectal cancer: A population-based study. Cancer. 109:718–726. 2007. View Article : Google Scholar : PubMed/NCBI

33 

Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J and Therasse P; RECIST Working Party, : Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer. 45:248–260. 2009. View Article : Google Scholar : PubMed/NCBI

34 

Yamaguchi T, Mori T, Takahashi K, Matsumoto H, Miyamoto H and Kato T: A new classification system for liver metastases from colorectal cancer in Japanese multicenter analysis. Hepatogastroenterology. 55:173–178. 2008.PubMed/NCBI

35 

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 26:2006–2012. 2008. View Article : Google Scholar : PubMed/NCBI

36 

Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B and Gruenberger T: Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surge Oncol. 17:2059–2065. 2010. View Article : Google Scholar

37 

Zorzi D, Chun YS, Madoff DC, Abdalla EK and Vauthey JN: Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol. 15:2765–2772. 2008. View Article : Google Scholar : PubMed/NCBI

38 

Veen T and Søreide K: Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis? World J Gastrointest Oncol. 9:98–104. 2017. View Article : Google Scholar : PubMed/NCBI

39 

Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA and Vauthey JN: Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 102:1175–1183. 2015. View Article : Google Scholar : PubMed/NCBI

40 

Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, Maru D, Overman MJ, Brudvik KW, Conrad C, Aloia TA and Vauthey JN: Is Hepatectomy justified for Patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery. 161:332–340. 2017. View Article : Google Scholar : PubMed/NCBI

41 

Bokemeyer C, Kohne C, Rougier P, Stroh C, Schlichting M and Van Cutsem E: Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. (ASCO Annual Meeting, abstract no. 3506). J Clin Oncol. 28:15s2010. View Article : Google Scholar

42 

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randamised phase 3 MRC COIN trial. Lancet. 377:2103–2114. 2011. View Article : Google Scholar : PubMed/NCBI

43 

Odisio BC, Yamashita S, Huang SY, Harmoush S, Kopetz SE, Ahrar K, Shin Chun Y, Conrad C, Aloia TA, Gupta S, et al: Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surge. 104:760–768. 2017. View Article : Google Scholar

44 

Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA and Maru DM: RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 258:619–626; discussion 626–627. 2013. View Article : Google Scholar : PubMed/NCBI

45 

Margonis GA, Kim Y, Spolverato G, Ejaz A, Gupta R, Cosgrove D, Anders R, Karagkounis G, Choti MA, Pawlik TM, et al: Association between specific mutations in KRAS Codon 12 and colorectal liver metastasis. JAMA Surg. 150:722–729. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 11 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kawagoe, S., Nakano, M., Uchino, K., Arimizu, K., Kajitani, T., Shimokawa, H. ... Baba, E. (2019). Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer. Molecular and Clinical Oncology, 11, 243-251. https://doi.org/10.3892/mco.2019.1894
MLA
Kawagoe, S., Nakano, M., Uchino, K., Arimizu, K., Kajitani, T., Shimokawa, H., Kusumoto, T., Ikejiri, K., Baba, E."Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer". Molecular and Clinical Oncology 11.3 (2019): 243-251.
Chicago
Kawagoe, S., Nakano, M., Uchino, K., Arimizu, K., Kajitani, T., Shimokawa, H., Kusumoto, T., Ikejiri, K., Baba, E."Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer". Molecular and Clinical Oncology 11, no. 3 (2019): 243-251. https://doi.org/10.3892/mco.2019.1894